CEVEC signs agreement with Roche for the use of CEVEC’s ELEVECTA® Technology in gene therapy

• Agreement will allow Roche to use CEVEC’s unique and proprietary ELEVECTA® Technology
  for AAV vector manufacturing
• The ELEVECTA® Stable Producer Cell Lines are designed to enable fully scalable, high-performance AAV vector production in suspension bioprocesses widely used in the biopharmaceutical industry

Cologne, Germany, November 10, 2020